AIM ImmunoTech Inc AIM announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen (rintatolimod) as a component of a Chemokine-Modulating (CKM) regimen for the treatment of early-stage triple-negative breast cancer (TNBC).
The topline results from the Phase 1 study confirm the positive findings previously presented at the 2022 Society for Immunotherapy of Cancer 37th Annual Meeting in a poster presentation.
Complete topline results confirm that treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC).
The results demonstrated that treatment was well-tolerated with mostly grade 1 or 2 treatment-related adverse events (TRAEs) without dose-limiting toxicities (DLTs) or delayed or immune-related toxicities.
DLT was defined as grade 3 or higher toxicities within the first three weeks. Secondary endpoints included pCR rate where 5/9 (56%) of patients attained pCR, and one more attained ypTmic.
Tumor and blood biomarkers were also analyzed in exploratory studies.
A Phase 2 study in early-stage TNBC is planned to determine if CKM, including Ampligen, may be a safe and effective alternative to pembrolizumab or pembrolizumab/NAC.
Price Action: AIM shares are up 6.26% at $0.62 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
